Detalhe da pesquisa
1.
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 29(14): 1795-1807, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-37905526
2.
Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
J Neurol
; 270(2): 1095-1119, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36376729
3.
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Mult Scler Relat Disord
; 70: 104472, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36566698
4.
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
Adv Ther
; 39(4): 1810-1831, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35211872
5.
Correction to: Communicating the relevance of neurodegeneration and brain atrophy to multiple sclerosis patients: patient, provider and researcher perspectives.
J Neurol
; 270(2): 1120-1126, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36574066